Genedrive ships first 96 SARS-CoV-2 Kits to US
(GDR ) said it has now shipped its first 96 SARS-CoV-2 Kits to the USA where manufacturing company, Beckman Coulter, will now commence initial sales activities.
The near-patient molecular diagnostics company entered a distribution agreement with Beckman Coulter last month, enabling it to sell and distribute Genedrive's 96 SARS-CoV-2 kits across the United States and Europe for its use on upper respiratory viral samples.
This agreement was the result of a previous agreement formed in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation with its RNAdvance Viral XP extraction kit.
Shares in Gendrive have almost tripled in value since the beginning of 2021. The stock was trading 13.46% higher this morning at 147.5p as a result of the Company’s announcement.
This shipment, which coincides with the formal launch of the Genedrive® 96 SARS-CoV-2 Kit by Beckman Coulter today, will not only allow the US-based manufacturing firm to commence initial sales activities but to prepare the market for a wider commercial rollout.
“This is an important milestone for Genedrive as the first shipments of our Genedrive 96 SAR-CoV-2 kit are exported to the US,” commented David Budd, CEO of Genedrive.
He added, “We are very optimistic about the US market for Covid PCR testing and it has market drivers that are favourable to the adoption of the genedrive assay: efficiency, ease of use, automation friendly, and scalability.”
Follow News & Updates from
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.